LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PETHEMA Foundation
• Treatments: 6-Mercaptopurine; Asparaginase; Cortisol succinate; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Mercaptopurine; Mitoxantrone; Prednisone; Vincristine

Criteria

Inclusion Criteria:

ALL BCR/ABL+ patients Age < 65 years No previous treatment

Exclusion Criteria:

1. Other LLA variability

2. Previous history of coronary valvular, hypertensive cardiopathy illness

3. Chronic hepatic illness

4. Chronic respiratory insufficiency

5. Renal insufficiency not caused by LLA

6. Severe neurological problems not caused by LLA

7. Severe affection of the performance status (grade 3-4 OMS gradation) not caused by LLA